Prescription Drugs: Cost Effectiveness
(asked on 3rd March 2026) - View Source
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the number of National Institute for Health and Care Excellence appraisals which are paused pending increases in the cost per quality-adjusted life year threshold in April.
This question was answered on 11th March 2026
There are currently two appraisals paused, at the request of the company, until the National Institute for Health and Care Excellence (NICE) has the power to apply the new cost-effectiveness threshold:
- Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]; and
- Ripretinib for treating advanced gastrointestinal stromal tumours after three or more treatments (review of TA881) [ID6496].
NICE anticipates that its cost-effectiveness threshold will increase in April 2026 and will provide a further update to stakeholders at that time.